Literature DB >> 19332983

BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Wanlong Ma1, Hagop Kantarjian, Chen-Hsiung Yeh, Zhong J Zhang, Jorge Cortes, Maher Albitar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19332983      PMCID： PMC2790522          DOI： 10.1159/000210060

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


× No keyword cloud information.
  24 in total

1.  Roots of clinical resistance to STI-571 cancer therapy.

Authors:  A Hochhaus; S Kreil; A Corbin; P La Rosée; T Lahaye; U Berger; N C Cross; W Linkesch; B J Druker; R Hehlmann; C Gambacorti- Passerini; G Corneo; M D'Incalci
Journal:  Science       Date:  2001-09-21       Impact factor: 47.728

2.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

Review 3.  STI571 (Gleevec) as a paradigm for cancer therapy.

Authors:  Brian J Druker
Journal:  Trends Mol Med       Date:  2002       Impact factor: 11.951

4.  Deletion of the Src homology 3 domain and C-terminal proline-rich sequences in Bcr-Abl prevents Abl interactor 2 degradation and spontaneous cell migration and impairs leukemogenesis.

Authors:  Z Dai; P Kerzic; W G Schroeder; I K McNiece
Journal:  J Biol Chem       Date:  2001-05-31       Impact factor: 5.157

5.  BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

Authors:  Nikolas von Bubnoff; Folker Schneller; Christian Peschel; Justus Duyster
Journal:  Lancet       Date:  2002-02-09       Impact factor: 79.321

6.  Homo- and hetero-oligomerization of the c-Abl kinase and Abelson-interactor-1.

Authors:  Pang-Dian Fan; Feng Cong; Stephen P Goff
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

7.  Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.

Authors:  D W Sherbenou; O Hantschel; L Turaga; I Kaupe; S Willis; T Bumm; R D Press; G Superti-Furga; B J Druker; M W Deininger
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

8.  Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development.

Authors:  Jason A Wertheim; Samanthi A Perera; Daniel A Hammer; Ruibao Ren; David Boettiger; Warren S Pear
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113

9.  Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

Authors:  Mohammad Azam; Robert R Latek; George Q Daley
Journal:  Cell       Date:  2003-03-21       Impact factor: 41.582

Review 10.  The BCR-ABL story: bench to bedside and back.

Authors:  Stephane Wong; Owen N Witte
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527
View more
  13 in total

1.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

2.  Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.

Authors:  Nóra Meggyesi; Lajos Kalmár; Sándor Fekete; Tamás Masszi; Attila Tordai; Hajnalka Andrikovics
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

3.  The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Christopher A Eide; Anupriya Agarwal; Lauren T Adrian; Huihong You; Amie S Corbin; Fei Yang; Richard D Press; Victor M Rivera; Julie Toplin; Stephane Wong; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

4.  Effector caspases and leukemia.

Authors:  Ying Lu; Guo-Qiang Chen
Journal:  Int J Cell Biol       Date:  2011-04-14

Review 5.  Hypothesis: Artifacts, Including Spurious Chimeric RNAs with a Short Homologous Sequence, Caused by Consecutive Reverse Transcriptions and Endogenous Random Primers.

Authors:  Zhiyu Peng; Chengfu Yuan; Lucas Zellmer; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  J Cancer       Date:  2015-05-01       Impact factor: 4.207

6.  Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.

Authors:  Junichiro Yuda; Toshihiro Miyamoto; Jun Odawara; Yasuyuki Ohkawa; Yuichiro Semba; Masayasu Hayashi; Koichi Miyamura; Mitsune Tanimoto; Kazuhito Yamamoto; Masafumi Taniwaki; Koichi Akashi
Journal:  Cancer Sci       Date:  2017-09-21       Impact factor: 6.716

Review 7.  It Is Imperative to Establish a Pellucid Definition of Chimeric RNA and to Clear Up a Lot of Confusion in the Relevant Research.

Authors:  Chengfu Yuan; Yaping Han; Lucas Zellmer; Wenxiu Yang; Zhizhong Guan; Wenfeng Yu; Hai Huang; D Joshua Liao
Journal:  Int J Mol Sci       Date:  2017-03-28       Impact factor: 5.923

8.  Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.

Authors:  R Kastner; A Zopf; S Preuner; J Pröll; N Niklas; P Foskett; P Valent; T Lion; C Gabriel
Journal:  Eur J Cancer       Date:  2013-12-20       Impact factor: 9.162

9.  The role of natural killer cells in chronic myeloid leukemia.

Authors:  Anna Carolyna Araújo Danier; Ricardo Pereira de Melo; Marcelo Henrique Napimoga; Maria Theresa Cerávolo Laguna-Abreu
Journal:  Rev Bras Hematol Hemoter       Date:  2011

10.  Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Abdul Aziz Baba; Azlan Husin; Abu Dzarr Abdullah; Rosline Hassan; Goh Ai Sim; S Fadilah Abdul Wahid; Ravindran Ankathil
Journal:  Hematol Rep       Date:  2012-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.